3 Key Takeaways
Plain English Summary- 01Core Finding
Because anti-TIGIT efficacy (real-world effectiveness in the trial) requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action.
- 02Study Evidence
Study design used a clinical evidence review protocol to track clinical outcomes.
- 03Practical Meaning
Benefits and risks vary by individual health history — discuss with a healthcare professional.
What This Means for You
Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation. Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR + cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
The Discovery
Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8 + T cell differentiation in cancer. Because anti-TIGIT efficacy (real-world effectiveness in the trial) requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy. Transcriptional profiling of intratumoral myeloid cells revealed an FcγR + cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8 + T cells expressed CD28 and upregulated CD226 upon treatment.
How It Works, Simply
This immunology research focuses on T cells · Immune response · Receptor targeting. Researchers evaluated it using a standard-of-care clinical practice · Clinical evidence review at the clinical practice stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action.
- 02Study Evidence
Study design used a clinical evidence review protocol to track clinical outcomes.
- 03Practical Meaning
Benefits and risks vary by individual health history — discuss with a healthcare professional.
Biological Mechanism & Study Design
Study Design & Cohort
Clinical evidence review
Standard-of-care clinical practice · Clinical evidence review · Clinical Practice
Biological Pathway & Modality
T cells · Immune response · Receptor targeting
Intervention: TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of
Experimental Findings & Endpoints
Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8 + T cell differentiation in cancer.
Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy.
Transcriptional profiling of intratumoral myeloid cells revealed an FcγR + cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8 + T cells expressed CD28 and upregulated CD226 upon treatment.
Clinical Translation & Practice Context
Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation.
Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR + cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
The Bottom Line · Clinical Pearl
“Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.”
Published in Immunity · Current Stage: Clinical Practice
